Andrey Ivanov, PhD

Research Program

Discovery and Developmental Therapeutics
Phone Number

404-727-0354
Email Address

andrey.ivanov@emory.edu

Biography

Andrey Ivanov, PhD, is an assistant professor in the Department of Pharmacology and Chemical Biology at Emory University School of Medicine and team lead for computational chemical biology and systems pharmacology at Emory Chemical Biology Discovery Center.

Dr. Ivanov is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University.

Education

Dr. Ivanov received his PhD in Organic and Computational Chemistry from Institute of Physiologically Active Compounds of the Russian Academy of Sciences in Russia.

Titles & Roles

Assistant Professor, Department of Pharmacology and Chemical Biology

Emory University School of Medicine

Research

Dr. Ivanov's research focuses on computational chemical biology and systems pharmacology to identify cancer targets and chemical probes.

Publications

Title/Journal	Authors	Publication Date
Protocol to discover actionable cancer vulnerabilities enabled by neomorph protein-protein interactions with the AVERON Notebook. STAR protocols	H Chen, B Revennaugh, H Fu, AA Ivanov	11/08/2024
Best practices to evaluate the impact of biomedical research software-metric collection beyond citations. Bioinformatics (Oxford, England)	A Afiaz, AA Ivanov, J Chamberlin, D Hanauer, CL Savonen, MJ Goldman, M Morgan, M Reich, A Getka, A Holmes, S Pati, D Knight, PC Boutros, S Bakas, JG Caporaso, G Del Fiol, H Hochheiser, B Haas, PD Schloss, JA Eddy, J Albrecht, A Fedorov, L Waldron, AM Hoffman, RL Bradshaw, JT Leek, C Wright	08/02/2024
AVERON notebook to discover actionable cancer vulnerabilities enabled by neomorph protein-protein interactions. iScience	H Chen, B Revennaugh, H Fu, AA Ivanov	06/21/2024
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers. The Journal of clinical investigation	Y Zhu, A Banerjee, P Xie, AA Ivanov, A Uddin, Q Jiao, JJ Chi, L Zeng, JY Lee, Y Xue, X Lu, M Cristofanilli, WJ Gradishar, CJ Henry, TW Gillespie, MA Bhave, K Kalinsky, H Fu, I Bahar, B Zhang, Y Wan	03/26/2024
Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's disease. The Journal of biological chemistry	Y Du, WJ Bradshaw, TM Leisner, JK Annor-Gyamfi, K Qian, FM Bashore, A Sikdar, FO Nwogbo, AA Ivanov, SV Frye, O Gileadi, PE Brennan, AI Levey, AD Axtman, KH Pearce, H Fu, VL Katis	12/01/2023
TMPRSS2 and SARS-CoV-2 SPIKE interaction assay for uHTS. Journal of molecular cell biology	D Cicka, Q Niu, M Qui, K Qian, E Miller, D Fan, X Mo, AA Ivanov, SG Sarafianos, Y Du, H Fu	08/03/2023
Evaluation of software impact designed for biomedical research: Are we measuring what's meaningful? ArXiv	A Afiaz, AA Ivanov, J Chamberlin, D Hanauer, CL Savonen, MJ Goldman, M Morgan, M Reich, A Getka, A Holmes, S Pati, D Knight, PC Boutros, S Bakas, JG Caporaso, G Del Fiol, H Hochheiser, B Haas, PD Schloss, JA Eddy, J Albrecht, A Fedorov, L Waldron, AM Hoffman, RL Bradshaw, JT Leek, C Wright	06/05/2023
Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. bioRxiv : the preprint server for biology	Y Du, WJ Bradshaw, TM Leisner, JK Annor-Gyamfi, K Qian, FM Bashore, A Sikdar, FO Nwogbo, AA Ivanov, SV Frye, O Gileadi, PE Brennan, AI Levey, AD Axtman, KH Pearce, H Fu, VL Katis	05/22/2023
Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. Acta pharmacologica Sinica	C Shu, X Zheng, A Wuhafu, D Cicka, S Doyle, Q Niu, D Fan, K Qian, AA Ivanov, Y Du, X Mo, H Fu	09/01/2022
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. Cell	X Mo, Q Niu, AA Ivanov, YH Tsang, C Tang, C Shu, Q Li, K Qian, A Wahafu, SP Doyle, D Cicka, X Yang, D Fan, MA Reyna, LAD Cooper, CS Moreno, W Zhou, TK Owonikoko, S Lonial, FR Khuri, Y Du, SS Ramalingam, GB Mills, H Fu	05/26/2022
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer. Bioorganic & medicinal chemistry	X Yang, D Fan, AH Troha, HM Ahn, K Qian, B Liang, Y Du, H Fu, AA Ivanov	09/01/2021
Hypomorph mutation-directed small-molecule protein-protein interaction inducers to restore mutant SMAD4-suppressed TGF-β signaling. Cell chemical biology	C Tang, X Mo, Q Niu, A Wahafu, X Yang, M Qui, AA Ivanov, Y Du, H Fu	05/20/2021
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	TK Owonikoko, B Dwivedi, Z Chen, C Zhang, B Barwick, V Ernani, G Zhang, M Gilbert-Ross, J Carlisle, FR Khuri, WJ Curran, AA Ivanov, H Fu, S Lonial, SS Ramalingam, SY Sun, EK Waller, GL Sica	03/01/2021
High expression of MKK3 is associated with worse clinical outcomes in African American breast cancer patients. Journal of translational medicine	X Yang, M Amgad, LAD Cooper, Y Du, H Fu, AA Ivanov	09/01/2020
NSD3S stabilizes MYC through hindering its interaction with FBXW7. Journal of molecular cell biology	V Gonzalez-Pecchi, AK Kwan, S Doyle, AA Ivanov, Y Du, H Fu	07/03/2020
Online informatics resources to facilitate cancer target and chemical probe discovery. RSC medicinal chemistry	X Yang, H Fu, AA Ivanov	06/01/2020
Explore Protein-Protein Interactions for Cancer Target Discovery Using the OncoPPi Portal. Methods in molecular biology (Clifton, N.J.)	AA Ivanov	01/01/2020
Hybrid Au/Si Disk-Shaped Nanoresonators on Gold Film for Amplified SERS Chemical Sensing. Nanomaterials (Basel, Switzerland)	G Barbillon, A Ivanov, AK Sarychev	11/08/2019
Protein Phosphatase 1-Targeting Small-Molecule C31 Inhibits Ebola Virus Replication. The Journal of infectious diseases	T Ammosova, CA Pietzsch, Y Saygideger, A Ilatovsky, X Lin, A Ivanov, N Kumari, M Jerebtsova, A Kulkarni, M Petukhov, A Üren, A Bukreyev, S Nekhai	11/22/2018
In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. Nature communications	CL Grzeskowiak, ST Kundu, X Mo, AA Ivanov, O Zagorodna, H Lu, RH Chapple, YH Tsang, D Moreno, M Mosqueda, K Eterovic, JJ Fradette, S Ahmad, F Chen, Z Chong, K Chen, CJ Creighton, H Fu, GB Mills, DL Gibbons, KL Scott	07/16/2018
RON kinase inhibition reduces renal endothelial injury in sickle cell disease mice. Haematologica	A Khaibullina, EA Adjei, N Afangbedji, A Ivanov, N Kumari, LEF Almeida, ZMN Quezado, S Nekhai, M Jerebtsova	05/01/2018
The OncoPPi Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery. Bioinformatics (Oxford, England)	AA Ivanov, B Revennaugh, L Rusnak, V Gonzalez-Pecchi, X Mo, MA Johns, Y Du, LAD Cooper, CS Moreno, FR Khuri, H Fu	04/01/2018
Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction. Assay and drug development technologies	J Xiong, VG Pecchi, M Qui, AA Ivanov, X Mo, Q Niu, X Chen, H Fu, Y Du	01/01/2018
Inhibition of HIV-1 infection in humanized mice and metabolic stability of protein phosphatase-1-targeting small molecule 1E7-03. Oncotarget	X Lin, N Kumari, C DeMarino, YS Kont, T Ammosova, A Kulkarni, M Jerebtsova, G Vazquez-Meves, A Ivanov, K Dmytro, A Üren, F Kashanchi, S Nekhai	09/29/2017
AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay. Molecular pharmacology	X Mo, Q Qi, AA Ivanov, Q Niu, Y Luo, J Havel, R Goetze, S Bell, CS Moreno, LA Cooper, MA Johns, FR Khuri, Y Du, H Fu	04/01/2017